Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (2)
  • MEK
    (2)
  • Akt
    (1)
  • Caspase
    (1)
  • EGFR
    (1)
  • ERK
    (1)
  • Endogenous Metabolite
    (1)
  • ROS
    (1)
  • Raf
    (1)
  • Others
    (13)
Filter
Search Result
Results for "

human lung cancer cell growth

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    23
    TargetMol | Inhibitors_Agonists
  • Inhibitory Antibodies
    2
    TargetMol | Inhibitory_Antibodies
  • Natural Products
    8
    TargetMol | Natural_Products
  • Recombinant Protein
    3
    TargetMol | Recombinant_Protein
  • Isotope Products
    2
    TargetMol | Isotope_Products
Triglycidyl isocyanurate
Tris(2,3-epoxypropyl) Isocyanurate, Teroxirone, TGIC, TGI
T224432451-62-9
Triglycidyl isocyanurate (Teroxirone) is a triazene triepoxide with antineoplastic and antiangiogenic activity. It inhibits growth of human non-small cell lung cancer cells by activating p53. Triglycidyl isocyanurate alkylates and cross-links DNA, thereby inhibiting DNA replication. It induces cell apoptosis and can be used for cancer research[1][2]. Triglycidyl isocyanurate is also used in various polyester powder coatings in the metal finishing industry.
  • Inquiry Price
Size
QTY
Lumichrome
7,8-Dimethylalloxazine
T50611086-80-2
Lumichrome is an endogenous compound in humans, produced by photodegradation of riboflavin. It utilizes a p53-dependent mechanism to inhibit growth and induce apoptosis in human lung cancer cells.
  • Inquiry Price
Size
QTY
JBJ-08-178-01
T2003082401867-58-9
JBJ-08-178-01, a mutant-selective tyrosine kinase inhibitor, targets (HER2) human epidermal growth factor receptor 2 and exhibits antitumoral activity. This compound not only diminishes HER2's kinase activity and protein levels through the induction of proteasomal degradation of the receptor but also shows promise in non-small-cell lung cancer research.
  • Inquiry Price
6-8 weeks
Size
QTY
SBI-183
T203429625403-59-0
SBI-183 is an orally active QSOX1 inhibitor (Kd: 20 μM). It can inhibit the proliferation and invasion phenotypes of renal carcinoma cell lines, triple-negative breast cancer cell lines, lung adenocarcinoma cell lines, and pancreatic ductal adenocarcinoma. In vivo, SBI-183 suppresses tumor growth in two human renal cell carcinoma xenograft mouse models.
  • Inquiry Price
Size
QTY
CEP-1612
CEP 1612,UNII-9K6U075027
T30795189036-01-9
CEP-1612 is a proteasomal inhibitor responsible for the proteolysis of proteins that regulate important cell cycles and apoptosis. CEP-1612 can induce p21WAF1 and p27KIP1 expression and apoptosis, and inhibit tumor growth of human lung cancer.
  • Inquiry Price
6-8 weeks
Size
QTY
Ajoene
T3562492285-01-3
Ajoene is a disulfide that has been found inA. sativumand has diverse biological activities, including antibacterial, anticancer, antiplatelet, and antioxidant properties.1,2,3,4It is active against Gram-positive (MICs = 5-160 µg/ml) and Gram-negative bacteria (MICs = 136-200 µg/ml), as well as yeasts (MICs = 10-20 µg/ml).1Ajoene is cytotoxic to mouse melanoma cells (IC50= 18 µM), as well as human colon, lung, mammary, and pancreatic cancer cells (IC50s = 7-41 µM).2It reduces tumor growth in a B16/BL6 mouse model of melanoma when administered at a dose of 25 mg/kg every other day and decreases the number of lung metastases when administered prior to tumor cell inoculation at doses ranging from 1-25 mg/kg. It inhibits ADP- or collagen-induced platelet aggregation in isolated baboon platelets when used at concentrations ranging from 75 to 150 µg/ml and in platelet-rich plasma isolated from baboons when administered at a dose of 25 mg/kg.3Ajoene (25 mg/kg) prevents thrombus formation on damaged arterial walls in heparinized pigs in anin situmodel of thrombogenesis.5It also reduces high-fat diet-induced hepatic steatosis, histopathological markers of liver damage, thiobarbituric acid reactive substances (TBARS) formation, and protein oxidation in a mouse model of non-alcoholic fatty liver disease (NAFLD).4 1.Naganawa, R., Iwata, N., Ishikawa, K., et al.Inhibition of microbial growth by ajoene, a sulfur-containing compound derived from garlicAppl. Environ. Microbiol.62(11)4238-4242(1996) 2.Taylor, P., Noriega, R., Farah, C., et al.Ajoene inhibits both primary tumor growth and metastasis of B16/BL6 melanoma cells in C57BL/6 miceCancer Lett.239(2)298-304(2006) 3.Teranishi, K., Apitz-Castro, R., Robson, S.C., et al.Inhibition of baboon platelet aggregation in vitro and in vivo by the garlic derivative, ajoeneXenotransplantation10(4)374-379(2003) 4.Han, C.Y., Ki, S.H., Kim, Y.W., et al.Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activationAntioxid. Redox Signal.14(2)187-202(2011) 5.Apitz-Castro, R., Badimon, J.J., and Badimon, L.A garlic derivative, ajoene, inhibits platelet deposition on severely damaged vessel wall in an in vivo porcine experimental modelThromb. Res.75(3)243-249(1994)
  • Inquiry Price
Size
QTY
2-deoxy-D-Glucose-13C6
2-deoxy-D-Glucose-13C6
T35683201612-55-7
2-deoxy-D-Glucose-13C6is intended for use as an internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS. 2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2It inhibits hexokinase, the enzyme that converts glucose to glucose-6-phosphate, as well as phosphoglucose isomerase, the enzyme that converts glucose-6-phosphate to fructose-6-phosphate.32-deoxy-D-Glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg ml.4,5In vivo, 2-deoxy-D-glucose (500 mg kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel .6 1.Kang, H.T., and Hwang, E.S.2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimeticLife Sci.78(12)1392-1399(2006) 2.Aft, R.L., Zhang, F.W., and Gius, D.Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell deathBr. J. Cancer87(7)805-812(2002) 3.Ralser, M., Wamelink, M.M., Struys, E.A., et al.A catabolic block does not sufficiently explain how 2-deoxy-D-glucose inhibits cell growthProc. Natl. Acad. Sci. USA105(46)17807-17811(2008) 4.Liu, H., Savaraj, N., Priebe, W., et al.Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C)Biochem. Pharmacol.64(12)1745-1751(2002) 5.Zhang, X.D., Deslandes, E., Villedieu, M., et al.Effect of 2-deoxy-D-glucose on various malignant cell lines in vitroAnticancer Res.26(5A)3561-3566(2006) 6.Maschek, G., Savaraj, N., Priebe, W., et al.2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivoCancer Res.64(1)31-34(2004)
  • Inquiry Price
Size
QTY
Erlotinib-13C6
Erlotinib-13C6
T359151211107-68-4
Erlotinib-13C6 (CP-358774-13C6) is a 13C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1]. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1].Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process[2]. [1]. Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
  • Inquiry Price
Size
QTY
Eicosapentaenoyl 1-propanol-2-amide
T364261638355-66-4
Monoacylglycerols (MAGs) of ω-3 polyunsaturated fatty acids have diverse physiological and health effects. In particular, MAGs containing docosahexaenoic acid or eicosapentaenoic acid have anti-proliferative properties against colon and lung cancer cell lines. Eicosapentaenoyl 1-propanol-2-amide is an EPA-containing MAG amide analog that inhibits the growth of human lung carcinoma A549 cells, producing 98.4% growth inhibition when applied at 3 μM. It is an analog of eicosapentaenoyl ethanolamide , a natural N-acylethanolamide that impacts aging and inflammation.
  • Inquiry Price
Size
QTY
Chromomycin A2
T368466992-70-7
Chromomycin A2 is an aureolic acid that has been found in several marine actinomycetes and has antibacterial and anticancer activities. Chromomycin A2 inhibits the growth of B. subtilis in an agar diffusion assay. It also inhibits the growth of human SGC7901 gastric cancer, HepG2 hepatocellular carcinoma, A549 lung epithelial adenocarcinoma, HCT116 colon cancer, and COC1 ovarian cancer cells, as well as human umbilical vein endothelial cells (HUVECs; IC50s = 4, 0.5, 3, 5, 5, and 8 nM, respectively). Chromomycin A2 (30 nM) halts the cell cycle in the G0/G1 phase and increases the protein levels of LC3A and LC3B in MALME-3M melanoma cells, indicating that it induces autophagy. It also increases the levels and promoter activity of the autophagic proteins ATG7 and ATG10 and reduces cell viability to 50% in human SCC-11 squamous cell carcinoma cells when used at a concentration of 30 nM.
  • Inquiry Price
Size
QTY
krc-108
T713821146944-35-5
KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. KRC-108 was also effective for the inhibition of tumor growth in human HT29 colorectal cancer and NCI-H441 lung cancer xenograft models in athymic BALB c nu nu mice. This molecule should serve as a useful lead for inhibitors targeting kinases and may lead to new therapeutics for the treatment of cancer. (source: Invest New Drugs. 2012 Apr;30(2):518-23. doi: 10.1007 s10637-010-9584-2. Epub 2010 Nov 16. ).
  • Inquiry Price
6-8 weeks
Size
QTY
c-Myc inhibitor 8
T726192173505-97-8
C-Myc Inhibitor 8 is an effective compound for cancer research, inhibiting cell viability across a range of cancer types and demonstrating growth suppression in human prostate and lung cancers within mouse models. This inhibitor specifically targets the c-Myc pathway, showcasing its potential utility in oncological studies.
  • Inquiry Price
8-10 weeks
Size
QTY
Bavituximab
Anti-PS MAb 3G4
T77401648904-28-3
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a monoclonal antibody targeting phosphatidylserine (PS) with vascular targeting and immunomodulatory properties, capable of reactivating anti-tumor immunity to inhibit tumor growth. It has anti-cancer activity and is frequently used with Paclitaxel and Carboplatin in non-small cell lung cancer studies.
  • Inquiry Price
Size
QTY
Necitumumab
LY3012211, LY 3012211, IMC-11F8, IMC11F8
T77459906805-06-9
Necitumumab (IMC-11F8) is a human monoclonal antibody directed against the epidermal growth factor (EGF) receptor, an anti-angiogenic agent used in the treatment of advanced non-small cell lung cancer, and may be used in cancer research.
  • Inquiry Price
Size
QTY
MS934
T791432756323-15-4
MS934, a novel VHL-recruiting MEK 1 2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM. It holds potential for researching various human cancers including melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma [1].
  • Inquiry Price
8-10 weeks
Size
QTY
22-(4′-py)-JA
22-(4′-Pyridinecarbonyl) jorunnamycin A
T795601178895-15-2
22-(4′-py)-JA, a semisynthetic derivative of junamycin A isolated from the Thai blue sponge (Xestospongia sp.), exhibits antimetastatic properties by inhibiting the AKT mTOR p70S6K signaling pathway. It also impedes tumor cell invasion and angiogenesis in human umbilical vein endothelial cells (HUVEC), while suppressing the expression of metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF). Its potent anticancer activity is particularly noted against non-small cell lung cancer (NSCLC) [1].
  • Inquiry Price
8-10 weeks
Size
QTY
Mollicellin I
T817691016605-29-0
Mollicellin I (compound 1), a depsidone, exhibits minimal growth inhibitory activity against human breast cancer (Bre04), human lung (Lu04), and human neuroma (N04) cell lines, with GI50 values exceeding 10 μg mL [1].
  • Inquiry Price
Size
QTY
Mollicellin H
T8177068455-09-4
Mollicellin H, a secondary metabolite from the fungus C. brasiliense, exhibits an array of biological activities such as immunomodulation, cytotoxicity, and anti-tumor properties. It demonstrates growth inhibitory effects (GI 50 s) on various human cell lines, including breast cancer (Bre04) at 5.1 μg mL, lung (Lu04) at 6.5 μg mL, and neuroma (N04) at 2.5 μg mL [1].
  • Inquiry Price
Size
QTY
(S)-Sabutoclax
(S)-BI-97C1
T846861228178-73-1
(S)-Sabutoclax ((S)-BI-97C1), an optically pure derivative of apogossypol, serves as a pan-active inhibitor of the antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. It effectively blocks the binding of BH3 peptides to key proteins in the family, including Bcl-XL, Bcl-2, Mcl-1, and Bfl-1, displaying inhibitory concentration (IC50) values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. Furthermore, (S)-Sabutoclax demonstrates potent efficacy in inhibiting the growth of various cancer cell lines, such as those from human prostate cancer, lung cancer, and lymphoma, with half-maximal effective concentration (EC50) values of 0.13, 0.56, and 0.049 μM, respectively. This compound is utilized in research focusing on apoptosis-based cancer therapies [1].
  • Inquiry Price
8-10 weeks
Size
QTY
1,4,5,6-Tetrahydroxy-7-prenylxanthone
TN24931001424-68-5
1,4,5,6-Tetrahydroxy-7-prenylxanthone exhibits anti-cancer activity, demonstrating moderate cytotoxicities against breast cancer (MDA-MB-435S) and lung adenocarcinoma (A549) cell lines, and shows moderate activity with GI50 values of 2.8 μM against the human leukaemic HL-60 cell line measured in vitro.
  • Inquiry Price
Size
QTY
2,3,23-Trihydroxy-12-oleanen-28-oic acid
TN2684102519-34-6
2β,3β,23α-Trihydroxy-12-oleanen-28-oic acid shows cytotoxic activities to human lung adenocarcinoma(A-549)cell lines. 2α,3β,23-Trihydroxyolean-12-en-28-oic acid and 2α,3β,23-trihydroxyurs-12-en-28-oic acid exhibit cytotoxicity in vitro against the growth of human cancer cells lines HepG-2,with IC50 values of 16.13 ± 3.83, 15.97 ± 2.47 uM, respectively.
  • Inquiry Price
Size
QTY
Griffipavixanthone
TN4166219649-95-3
Griffipavixanthone inhibits the growth of human Non-small-cell lung cancer H520 cells in dose- and time-dependent manners, it induces cell apoptosis through mitochondrial apoptotic pathway accompanying with ROS production. It can inhibit tumor metastasis
  • Inquiry Price
Size
QTY
Dexylosyltubeimoside Ⅲ
TN8178
Dexylosyltubeimoside III (compound 3) is a cyclic diglycoside isolated from Actinostemma lobatum MAXIM. It exhibits in vitro anticancer activity, inhibiting the growth of human esophageal cancer cell line ECA109 (IC50=22.37 μM), lung cancer cell line A549 (IC50=27.27 μM), and gastric cancer cell line MGC-803 (IC50=36.85 μM).
  • Inquiry Price
Size
QTY